Readystate Asset Management LP Inhibrx, Inc. Transaction History

Readystate Asset Management LP

  • $3.08 Trillion
  • Q2 2024

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024
BUY
$14.5 - $38.0 $200,665 - $525,882
13,839 New
13,839 $526 Million

Others Institutions Holding INBX

# of Institutions
2
Shares Held
25.3K
Call Options Held
0
Put Options Held
0
View Full List

About Inhibrx, Inc.

INBX Quotes by TradingView
  • Ticker INBX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,057,700
  • Market Cap $617M
  • Description
  • Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcin...
More about INBX
Track This Portfolio

Track Readystate Asset Management LP Portfolio

Follow Readystate Asset Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Readystate Asset Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Readystate Asset Management LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email